[go: up one dir, main page]

MA38175A1 - Lactames fusionnés à un aryle et hétéroaryle - Google Patents

Lactames fusionnés à un aryle et hétéroaryle

Info

Publication number
MA38175A1
MA38175A1 MA38175A MA38175A MA38175A1 MA 38175 A1 MA38175 A1 MA 38175A1 MA 38175 A MA38175 A MA 38175A MA 38175 A MA38175 A MA 38175A MA 38175 A1 MA38175 A1 MA 38175A1
Authority
MA
Morocco
Prior art keywords
heteroaryl
aryl
compounds
salts
lactams
Prior art date
Application number
MA38175A
Other languages
English (en)
Other versions
MA38175B1 (fr
Inventor
Martin Paul Edwards
Robert Arnold Kumpf
Pei-Pei Kung
Indrawan James Mcalpine
Sacha Ninkovic
Eugene Yuanjin Rui
Scott Channing Sutton
John Howard Tatlock
Martin James Wythes
Luke Raymond Zehnder
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA38175A1 publication Critical patent/MA38175A1/fr
Publication of MA38175B1 publication Critical patent/MA38175B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne des composés de formule générale (i), des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques contenant lesdits composés et sels, et des méthodes d'utilisation desdits composés, sels et compositions pour traiter une croissance cellulaire anormale, y compris le cancer. Dans la formule générale (i), r
MA38175A 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle MA38175B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
PCT/IB2013/060682 WO2014097041A1 (fr) 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle

Publications (2)

Publication Number Publication Date
MA38175A1 true MA38175A1 (fr) 2018-08-31
MA38175B1 MA38175B1 (fr) 2018-11-30

Family

ID=49917684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38175A MA38175B1 (fr) 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle

Country Status (46)

Country Link
US (3) US9040515B2 (fr)
EP (2) EP2935238B1 (fr)
JP (1) JP5909308B2 (fr)
KR (1) KR101712441B1 (fr)
CN (1) CN104870435B (fr)
AP (1) AP2015008574A0 (fr)
AR (1) AR094174A1 (fr)
AU (1) AU2013365908C1 (fr)
BR (1) BR112015014678B1 (fr)
CA (1) CA2893339C (fr)
CL (1) CL2015001733A1 (fr)
CR (2) CR20200273A (fr)
CU (1) CU24414B1 (fr)
CY (2) CY1119883T1 (fr)
DK (2) DK3339303T3 (fr)
DO (1) DOP2015000157A (fr)
EA (1) EA028317B1 (fr)
EC (1) ECSP15031579A (fr)
ES (2) ES2658974T3 (fr)
GE (1) GEP201706718B (fr)
GT (1) GT201500190A (fr)
HR (2) HRP20180060T1 (fr)
HU (2) HUE050009T2 (fr)
IL (1) IL239520B (fr)
LT (2) LT3339303T (fr)
MA (1) MA38175B1 (fr)
MD (1) MD4664C9 (fr)
ME (2) ME03793B (fr)
MX (2) MX2015008058A (fr)
MY (2) MY192259A (fr)
NO (1) NO2961649T3 (fr)
NZ (1) NZ708801A (fr)
PE (1) PE20151090A1 (fr)
PH (1) PH12015501367B1 (fr)
PL (2) PL2935238T3 (fr)
PT (2) PT2935238T (fr)
RS (2) RS60582B9 (fr)
SG (1) SG11201504076XA (fr)
SI (2) SI2935238T1 (fr)
TN (1) TN2015000281A1 (fr)
TR (1) TR201802791T4 (fr)
TW (1) TWI546293B (fr)
UA (1) UA111305C2 (fr)
UY (2) UY38712A (fr)
WO (1) WO2014097041A1 (fr)
ZA (1) ZA201504437B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075084A1 (fr) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
CA2862289C (fr) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (fr) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
GEAP201814347A (en) * 2014-06-17 2018-08-10 Pfizer Substituted dihydroisoquinoline compounds
WO2015193768A1 (fr) * 2014-06-17 2015-12-23 Pfizer Inc. Lactames à fusion aryle à utiliser en tant que modulateurs ezh2
CA2965729A1 (fr) * 2014-10-28 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
CN107428722B (zh) * 2015-03-27 2021-04-20 先正达参股股份有限公司 杀微生物的杂二环衍生物
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (fr) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Formes cristallines de (r)-n-((4-méthoxy-6-méthyl-2-oxo-1,2-dihydropyridin-3-yl)méthyl)-2-méthyl-1-(1-(1-(2,2,2-trifluoroéthyl)pipéridin-4-yl)éthyl)-1h-indole-3-carboxamide
EP3378859B1 (fr) 2015-11-19 2019-10-30 Jiangsu Hengrui Medicine Co., Ltd. Dérivé du benzofurane, son procédé de préparation et son utilisation en médecine
AU2017260854B2 (en) * 2016-05-05 2020-01-30 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
CN108699002B (zh) * 2016-11-11 2021-11-09 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
EP3558363A1 (fr) 2016-12-21 2019-10-30 Amgen Inc. Formulations d'anticorps anti-tnf alpha
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018210296A1 (fr) 2017-05-18 2018-11-22 江苏恒瑞医药股份有限公司 Utilisation d'un inhibiteur d'ezh2 combiné à un inhibiteur de btk dans la préparation d'un médicament pour le traitement d'une tumeur
TWI772424B (zh) 2017-05-18 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種苯并呋喃類衍生物游離鹼的晶型及製備方法
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
JP7201400B2 (ja) 2017-11-14 2023-01-10 ファイザー・インク Ｅｚｈ２阻害剤組合せ療法
BR112020015583B1 (pt) 2018-01-31 2022-12-06 Mirati Therapeutics, Inc Composto, composição farmacêutica e seu uso para tratar câncer
JP2021527064A (ja) * 2018-06-07 2021-10-11 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｐｒｃ１阻害剤及びそれを用いた治療方法
EP3823671B1 (fr) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition de sous-unités de prc2 permettant de traiter des troubles oculaires
EP3870173A4 (fr) * 2018-10-24 2022-06-22 Vanderbilt University Modulateurs et inhibiteurs de wdr5
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
WO2020219448A1 (fr) 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Dérivés de naphtyridine en tant qu'inhibiteurs de prc2
EP3980422A1 (fr) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Dérivés d'imidazo [1,2-c]pyrimidine utilisés comme inhibiteurs de prc2 pour le traitement du cancer
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
MX2023001603A (es) * 2020-08-13 2023-03-07 Hanmi Pharmaceutical Co Ltd Derivados de dioxoloisoquinolinona novedosos y uso de los mismos.
CN116457348B (zh) * 2021-02-26 2024-11-26 南京迈晟科技有限责任公司 Ezh2抑制剂及其用途
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物
CN118978498B (zh) * 2024-10-22 2025-04-01 浙江雅辰药物科技股份有限公司 一种5-羟甲基四氢呋喃-3-醇的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
AU2006279548A1 (en) 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2011103016A2 (fr) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions et méthodes d'inhibition d'ezh2
EP2566328B1 (fr) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
JP5889875B2 (ja) 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
CN102970869B (zh) 2010-05-07 2014-07-16 葛兰素史密斯克莱有限责任公司 吲哚
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
WO2012068589A2 (fr) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
WO2012118812A2 (fr) * 2011-02-28 2012-09-07 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CN103987842A (zh) 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2884848C (fr) 2012-09-28 2017-08-22 Pfizer Inc. Composes de benzamide et heterobenzamide
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
AP2015008510A0 (en) 2012-12-21 2015-06-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
MX2015008114A (es) 2012-12-21 2015-11-06 Sanofi Sa Derivados de exendina-4.
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
LT2935312T (lt) 2012-12-21 2018-10-25 F. Hoffmann-La Roche Ag Peptidai, kaip oksitocino agonistai
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
WO2014100620A2 (fr) 2012-12-21 2014-06-26 Plexxikon Inc. Composés et procédés pour la modulation de kinase, et indications associées
GEAP201814347A (en) 2014-06-17 2018-08-10 Pfizer Substituted dihydroisoquinoline compounds

Also Published As

Publication number Publication date
MX2020002924A (es) 2020-07-22
LT2935238T (lt) 2018-02-26
US20170233368A1 (en) 2017-08-17
SI3339303T1 (sl) 2020-09-30
ME02980B (fr) 2018-10-20
TN2015000281A1 (fr) 2016-10-03
TWI546293B (zh) 2016-08-21
BR112015014678B1 (pt) 2021-12-07
HRP20180060T1 (hr) 2018-02-23
PL3339303T3 (pl) 2021-01-25
RS56815B1 (sr) 2018-04-30
AU2013365908C1 (en) 2018-01-25
NO2961649T3 (fr) 2018-02-17
EP3339303B9 (fr) 2021-07-21
GEP201706718B (en) 2017-08-10
JP2016507497A (ja) 2016-03-10
EP3339303B1 (fr) 2020-06-24
EA028317B1 (ru) 2017-11-30
EP2935238B1 (fr) 2017-12-27
ES2658974T3 (es) 2018-03-13
CU20150062A7 (es) 2015-11-27
TW201446753A (zh) 2014-12-16
DK3339303T3 (da) 2020-08-10
MD20150052A2 (ro) 2015-12-31
KR101712441B1 (ko) 2017-03-07
SI2935238T1 (en) 2018-04-30
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
ZA201504437B (en) 2016-07-27
JP5909308B2 (ja) 2016-04-26
EP2935238A1 (fr) 2015-10-28
MD4664B1 (ro) 2019-12-31
PH12015501367B1 (en) 2018-08-03
UY35225A (es) 2014-07-31
UA111305C2 (uk) 2016-04-11
AR094174A1 (es) 2015-07-15
US20140179667A1 (en) 2014-06-26
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
DOP2015000157A (es) 2015-11-30
HRP20201194T2 (hr) 2021-09-17
GT201500190A (es) 2016-01-21
HK1208866A1 (en) 2016-03-18
HUE050009T2 (hu) 2020-11-30
CN104870435A (zh) 2015-08-26
CR20150279A (es) 2015-09-03
EP3339303A1 (fr) 2018-06-27
EA201590879A1 (ru) 2015-12-30
ECSP15031579A (es) 2017-08-31
KR20150100823A (ko) 2015-09-02
MY176307A (en) 2020-07-28
DK2935238T3 (en) 2018-01-22
MY192259A (en) 2022-08-12
PE20151090A1 (es) 2015-08-07
ES2808987T3 (es) 2021-03-02
CR20200273A (es) 2020-09-23
PT3339303T (pt) 2020-07-30
WO2014097041A1 (fr) 2014-06-26
CA2893339A1 (fr) 2014-06-26
CN104870435B (zh) 2016-12-07
BR112015014678A2 (pt) 2017-07-11
CY1123237T1 (el) 2021-10-29
US9040515B2 (en) 2015-05-26
RS60582B9 (sr) 2021-09-30
HUE038238T2 (hu) 2018-10-29
AP2015008574A0 (en) 2015-07-31
ES2808987T9 (es) 2021-11-29
US10246433B2 (en) 2019-04-02
UY38712A (es) 2020-06-30
PH12015501367A1 (en) 2015-09-02
US20150175572A1 (en) 2015-06-25
TR201802791T4 (tr) 2018-03-21
CL2015001733A1 (es) 2015-10-23
RS60582B1 (sr) 2020-08-31
AU2013365908B2 (en) 2017-07-20
IL239520A0 (en) 2015-08-31
HRP20201194T1 (hr) 2020-11-13
CA2893339C (fr) 2017-06-13
MA38175B1 (fr) 2018-11-30
CY1119883T1 (el) 2018-06-27
AU2013365908A1 (en) 2015-06-11
LT3339303T (lt) 2020-09-10
ME03793B (fr) 2021-04-20
CU24414B1 (es) 2019-05-03
IL239520B (en) 2018-05-31
MX2015008058A (es) 2015-10-30
MD4664C9 (ro) 2020-07-31

Similar Documents

Publication Publication Date Title
MA38175A1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA38138A1 (fr) Dérivés inédits de quinolone
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
UA111770C2 (uk) Інгібітори бромдомену
MX2014012695A (es) Derivados de isoindolona.
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MX2016009403A (es) Compuestos heterociclicos.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA025302B8 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA38240A1 (fr) Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides
MA38999A1 (fr) Nouveaux composés hétérocycliques
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
UA107455C2 (uk) Похідні індолу як протиракові агенти
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
TR201819805T4 (tr) Flavaglin türevleri̇.
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer